An innovative Montreal-based research collaboration aims to improve the detection of type 2 diabetes (T2D) in people who are at high risk, using artificial intelligence (AI)-based wearable technologies and electronic health record systems.
The DECIDE-CV program is a three-year partnership between Boehringer Ingelheim Canada, the Research Institute of the McGill University Health Centre (RI-MUHC), the McGill University Health Centre (MUHC) Foundation, HOP Tech, and MEDTEQ+. The partnership is one of the first multi-disciplinary efforts aimed at using AI-based technologies to support people living with T2D.
T2D is a complex disease that often goes undiagnosed until a significant health issue occurs, such as a major cardiovascular event. The DECIDE-CV program signals a paradigm shift in healthcare, transitioning from treating health issues when they arise, to striving to prevent individuals from getting sick in the first place. It also encompasses the latest thinking in digital and behavioural sciences, to support individuals more effectively beyond medication.
This partnership exemplifies how innovative digital solutions can promote better health outcomes for patients and contribute to sustainable, transformative changes aimed at enhancing the healthcare system for all. Learn more about the partnership.